top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Cotinine Test Devices Market Market : Technological Growth Map over Time to Understand the Industry Growth Rate

0 votes
4 views

Cotinine Test Devices Market: Overview

  • Cotinine is nicotine’s first-stage metabolite, a toxic alkaloid which activates the autonomic ganglia and the central nervous system in humans. Nicotine is a drug that is consumed by nearly every member with addiction to tobacco products, whether through direct contact or second-hand inhalation. As an active ingredient in cigarette cessation treatments such as nicotine gum, transdermal patches, and nasal sprays, nicotine is also commercially available in addition to tobacco.
  • The cotinine test is based on the principle of mutual binding of antigen-antibody. The test device contains a membrane strip pre-coated in the region of the test line with a cotinine antigen.

Report Overview @ https://www.transparencymarketresearch.com/cotinine-test-devices-market.html

Key Drivers of Global Cotinine Test Devices Market

  • Rise in awareness about smoking health hazards and smoking cessation therapy
  • Smoking cigarettes is a major cause of lung cancer and other heart and respiratory diseases. Awareness about these health hazards has influenced individuals to take smoking cessation therapy.
  • Awareness through information brochures, television advertisements, newspapers, and other media has proved to be effective in restricting the nicotine addiction crisis to some extent
  • Mere recognition could not have helped market growth, but concurrent promotion of smoking cessation therapy and related products offered a viable alternative to smoking for cigarette addicts
  • In the initial stages, convincing results motivated other addicts to try cotinine testing devices. Cessation of smoking campaigns has thus proven to be one of the market’s major drivers.

Request PDF Sample of Cotinine Test Devices Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74362

Cassettes Segment Accounted for Largest Revenue Share of Global Market

  • Based on device type, the global cotinine test devices market can be classified into cassettes, strips, and readers
  • Key players operating in the global cotinine test devices market focus on boosting the production of cassettes and strips due to high demand in cotinine testing
  • The cassettes and strips segments are expected to dominate the global cotinine test devices market between 2019 and 2027
  • Based on sample type, the global cotinine test devices market can be categorized into urine, saliva, and blood

North America to Lead Global Cotinine Test Devices Market

  • In terms of region, the global cotinine test devices market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America is projected to dominate the global cotinine test devices market due to increase in the number of smokers in the region. The Centers for Disease Control and Prevention (CDC) launched a debatable advertising campaign featuring graphic photos, videos, and stories of smokers to reduce smoking prevalence.
  • Smoking bans, anti-smoking messages, and high taxes on tobacco have influenced chain smokers to quit smoking in the U.S., leading to decline in the number of cigarette smokers. As of 2017, only about 15% of the population were smokers, whereas the percentage of smokers in 2016 and 2015 was 18% and 17%, respectively.

Pre Book “Cotinine Test Devices Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=74362&ltype=S

Key Manufacturers Operating in Global Cotinine Test Devices Market

The global cotinine test devices market was highly fragmented in 2018. Key players in the global cotinine test devices market are:

  • Germaine Laboratories, Inc.
  • LifeSign LLC.
  • Mossman Associates
  • Jant Pharmacal Corporation
  • AlcoPro
  • Abbott

More Trending Reports by Transparency Market Research –

Erectile Dysfunction Drugs Market: prnewswire.com/news-releases/erectile-dysfunction-drugs-market-is-expected-to-reach-usd-34-billion-globally-in-2019-transparency-market-research-228593931.html

Veterinary Drugs Market: prnewswire.com/news-releases/veterinary-drugs-market-to-reach-us267-bn-by-2024-rising-inclination-toward-ensuring-health-and-wellness-of-companion-animals-to-aid-growth-says-tmr-615866193.html

posted Feb 11 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report titled, “Ultrasound Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global ultrasound devices market was valued at US$ 6.5 Bn in 2017. It is projected to expand at a CAGR of 5.6% from 2018 to 2026. Surge in incidence of various disorders such as cardiovascular diseases, respiratory, and abdominal disorders cases is anticipated to boost the demand for ultrasound devices during the forecast period. North America and Europe are projected to dominate the global ultrasound devices market owing to higher rate of adoption and awareness regarding ultrasound devices. Asia Pacific, Latin America, and Middle East & Africa are potential markets for ultrasound devices. The market in Asia Pacific is expected to expand at a CAGR of 6.2% from 2018 to 2026.

Cost-effective ultrasound devices to detect complex disorders to drive global market

Increase in number of cases of various disorders, across the globe, drives the ultrasound devices market. According to the WHO, cardiovascular diseases accounted for an estimated 17.7 million deaths in 2015, representing 31% of all global deaths. Among these, an estimated 7.4 million were due to coronary heart disease, and 6.7 million were due to stroke. This is likely to increase the number of diagnostic procedures; consequently, propelling the global ultrasound devices market.

Request PDF Sample of Ultrasound Devices Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2483

Compact/Handheld ultrasound devices to be highly lucrative segment

Compact/handheld ultrasound devices is an emerging segment of the ultrasound devices market. The compact/handheld ultrasound devices segment is likely to expand at a significant CAGR. Moreover, the trolley/cart-based ultrasound devices segment is likely to hold a major share due to technologically advanced product adopted by diagnostic centers. Moreover, increased adoption of portable ultrasound devices for point-of-care applications, it cannot outpace the trolley/cart based ultrasound devices, as they offer more accurate diagnostic capabilities and high performance.

Radiology/General imaging segment accounted for dominant share of global ultrasound devices market

In terms of application, the global ultrasound devices market has been segmented into various applications. Radiology/general imaging is projected to be a highly attractive segment during the forecast period. Rising sophistication in diagnostic imaging platform, which enables emerging countries to provide 24X7 diagnostic services to its clients is likely to propel this segment during the forecast period.

Diagnostic centers to be promising segment

In terms of end-user, the global ultrasound devices market has been segregated into hospital & surgical centers, diagnostic centers, ambulatory surgical centers, and others. The diagnostic centers segment held a major share of the global market in 2017. Expansion of the segment can be attributed to the availability of multiple service options and devices and tie-ups with health care companies in order to enhance health care products and service offerings. Moreover, diagnostic centers are the preferred choice due to availability of advanced technology and better health care services. The hospital & surgical centers segment is expanding at a high growth rate, especially in developed economies, due to rise in geriatric population and increasing health care infrastructure and support. Moreover, rise in demand for ultrasound devices in ambulatory surgical centers during medical emergency is projected to drive the segment.

Enquiry for Discount on “Ultrasound Devices Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2483

North America expected to dominate global market

In terms of region, the global ultrasound devices market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe dominated the global ultrasound devices market in 2017. In terms of revenue, the market in Europe was valued at US$ 2.1 Bn in 2017, owing to a highly developed health care sector, increase in awareness among health care providers about ultrasound devices, and continuous evolution of ultrasound devices. This region offers significant opportunity to the ultrasound devices market. The ultrasound devices market in Asia Pacific is anticipated to expand at a CAGR of 6.2% during the forecast period, due to increase in awareness about ultrasound devices for diagnostic and therapeutic. Moreover, expansion of the health care sector in countries such as China, Japan, and India offers immense potential in this region. Additionally, technological advancements and increase in rate of adoption of ultrasound devices products are expected to propel the market in the region during the forecast period.

GE Healthcare and Koninklijke Philips N.V. anticipated to lead global market

The global ultrasound devices market is highly fragmented in terms of number of players providing different products. Key players in the global ultrasound devices market include GE Healthcare, Koninklijke Philips N.V., Canon Medical Systems Corporation, Hitachi, Ltd., Siemens Healthineers, Mindray Medical International Limited, Samsung Medison Co., Ltd., Fujifilm Holdings Corporation, Esaote SpA, and Analogic Corporation. Expansion of product portfolio through mergers and acquisitions is a key strategy followed by several global players.

0 votes

The Europe PRP market is highly fragmented and competitive with the presence of a large number of small and large multinational players across the globe, says a Transparency Market Research (TMR). 

Some of the established players operating in the Europe platelet rich plasma market are Arthrex, Inc., Biomet, Inc., and EmCyte Corporation. Altogether, these three players have dominated the Europe PRP market in 2013. The market is witnessing entry of several new players as well. This is expected to intensify market completion in the coming years. 

The analyst of TMR, noted Europe platelet rich plasma market at US$42.1 mn in 2013. The market is expected to rise at a CAGR of 8.30% from 2014 to 2022. Rising at this CAGR, the market is predicted to attain a valuation of US$ 87.2 mn by the end of forecast period. 

On the basis of countries, the UK dominated the Europe platelet rich plasma market in 2013. The country is expected to continue its dominance during the forecast year as well. This is mainly because of the increasing prevalence of reconstructive and orthopedic procedures in the country. Based on application, the orthopedic surgery segment led the platelet rich plasma market. In the base year, the segment led the market with 38.3% of lion’s share. This is mainly due to the increasing geriatric population and the rising count of sports and orthopedic injuries in the region. 

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4761

Growing Adoption of Platelet-Rich Plasma to Drive Market 

The global platelet-rich plasma market is expected to garner an impressive CAGR over the forecast period. Rising incidences of sports injuries, growing use of platelet-rich plasma in various therapeutic areas, increasing number of androgenic alopecia patients, and rise in the prevalence of arthritis are the key factors attributed to offer a significant push to the platelet-rich plasma market. 

The use of platelet rich plasma therapy is tremendously increased after 2009 owing to the promising solution offer by them to the patients. The intense research and development by the key players has increased the application scope of therapeutic. Moreover, platelet rich plasma has minimum side effects on the patient. This is anticipated to increase the adoption for the platelet rich plasma therapies thereby fueling the Europe platelet rich plasma market. 

 In addition, the rising inclination of people towards platelet rich plasma therapies to treat several sports injuries is another strong factor expected to offer a significant boost to the Europe platelet rich plasma market.  Along with this, platelet rich plasmas is also used is wide range of cosmetic surgeries and hair regain therapies. This is expected to fuel the Europe platelet rich plasma market in the coming years. 

Increasing Incidence of Treatment failure to Impede Growth 

Despite of several drivers, growth of the Europe platelet rich plasma market is hindered by several factors. One of the most prominent restraints of the market is soaring costs of therapies and devices of platelet rich plasma therapeutics. Along with this, that immunity system of human body rejects injection of plasma thereby causing a treatment failure. This is expected to dampen the prospects of the Europe platelet rich plasma market during the forecast period. 

Nevertheless, factors such as launch of several advanced devices for platelet rich plasmas and the increasing awareness about platelet rich plasma therapy may offer lucrative opportunities to the growth of the Europe platelet rich plasma market. 

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Diabetes Drugs Market: prnewswire.com/news-releases/diabetes-drugs-market-value-to-reach-us584-billion-by-the-end-of-2025-transparency-market-research-663610203.html

0 votes

According to a new report published by Transparency Market Research (TMR)  titled “Veterinary Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”, the global veterinary molecular diagnostics market was valued at US$ 377.2 Mn in 2016 and is projected to expand at a CAGR of 8.6% from 2017 to 2025 to reach value of US$ 792.5 Mn by 2025. This report offers a thorough understanding of the global veterinary molecular diagnostics market including key trends, drivers, restraints, and opportunities.

Rising awareness about molecular diagnostics among veterinarians and general public in both developed and developing countries is expected to drive the global veterinary molecular diagnostics market in the near future. High test sensitivity and specificity and development of new products against new diseases in animals are also driving the global veterinary molecular diagnostics market. The Asia Pacific region is witnessing gradual adoption of new technologies in veterinary molecular diagnostics, increasing animal health care expenditure, and changing dynamics of the in vitro diagnostics industry. Due to this, the veterinary molecular diagnostics market in Asia Pacific is anticipated to expand at a CAGR of 9.2% from 2017 to 2025.

The global veterinary molecular diagnostics market has been witnessing a significant shift from manual systems toward automated systems. Incidence of new diseases such as helminth parasitic diseases and protozoal parasitic diseases is rising. Development of better methods such as molecular diagnostics to detect and fight these diseases promptly is expected to drive the global veterinary molecular diagnostics market in the next few years. Factors indicating the growing importance of livestock diagnostics, medicines, and vaccines such as surging demand for improved nutrition (particularly, animal protein), limited natural resources, and widened focus on food safety are anticipated to boost the veterinary molecular diagnostics market during the forecast period.

Request PDF Sample of Veterinary Molecular Diagnostics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42437

Technological Advancements to drive Global Market

Veterinary molecular diagnostics offers several advantages over the conventional diagnostic techniques such as rapid turnaround time (2.5–3 hours), high test sensitivity and specificity, and better differentiation between avirulant and birulent strains. These added advantages are anticipated to drive the global veterinary molecular diagnostics market during the forecast period. Technological advancements in devices and reagents available for veterinary molecular diagnostics have enabled veterinarians to provide proper emergency assistance to patients.

Improvement in the health care infrastructure, government campaigns, and increase in per capita income have raised awareness regarding the importance of preventive care and sophisticated diagnostic tools among veterinarians and general public. Pet owners are becoming more conscious about proper and timely diagnosis of disease suffered by their pets. This rise in awareness among the people in both developed and developing countries is expected to drive the global veterinary molecular diagnostics market in the next few years. Sophisticated molecular diagnostic instruments and assays are well-recognized and validated for proper testing. However, high costs associated with these systems and assays presents a significant challenge for the market.

Kits & Reagents Segment dominates the Market, followed by Instruments & Software Segment

The global veterinary molecular diagnostics market has been segmented based on product, technology, animal type, disease indication, end-user, and geography. Based on product, the global veterinary molecular diagnostics market has been segmented into instruments & software, kits & reagents, and services. The kits & reagents segment is expected to dominate the global veterinary molecular diagnostics market during the forecast period. This is attributable to the rising number of customized kits and reagents used in disease detection and health surveillance processes. Growing inclination toward preventive animal care and diagnosis is leading to high-volume processing, which augments the demand for high-throughput instruments and software.

Buy Now “Veterinary Molecular Diagnostics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=42437&ltype=S

Polymerase Chain Reaction (PCR) to be the Most Promising Technology

Based on technology, the market has been segmented into polymerase chain reaction (PCR), microarrays, and DNA sequencing. The polymerase chain reaction (PCR) segment is anticipated to remain highly lucrative during the forecast period, owing to several advantages over the conventional detection methods; for example, quick and accurate results. In terms of animal type, the market has been segregated into companion animals and livestock animals. Based on disease indication, the market has been segmented into vector-borne diseases, respiratory pathogens detection, diarrhea pathogens detection, and others. Based on end-user, the market has been segmented into hospitals/clinics and reference laboratories.

Asia Pacific to offer Lucrative Growth Opportunities

Geographically, the global veterinary molecular diagnostics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to be the largest market for veterinary molecular diagnostics between 2017 and 2025. Growth of the market in the region can be attributed to increase in government and private funding and large volume of tests performed in the region.

The Asia Pacific region is witnessing gradual adoption of new veterinary molecular diagnostics technologies, increase in health care expenditure, and change in dynamics of the in vitro diagnostics industry. High adoption of veterinary diagnostics drugs, vaccines, and medicated feed additives for the well-being of rapidly increasing population of livestock animals in the region makes Asia Pacific one of the most lucrative markets for veterinary molecular diagnostics

Key Players such as IDEXX Laboratories, Inc. and VCA, Inc. likely to continue to lead Global Veterinary Molecular Diagnostics Market

Major companies competing in the global veterinary molecular diagnostics market and profiled in the report are IDEXX Laboratories, Inc., VCA, Inc., Thermo Fisher Scientific, Inc., Novacyt Group, QIAGEN N.V., Biomedica Medizinprodukte GmbH & Co KG, HealthGene Corporation, and Bioneer. IDEXX Laboratories dominates the market due to high market penetration of its flagship products in the global veterinary molecular diagnostics market.

0 votes

Transparency Market Research (TMR) has published a new report titled, “Anticoagulants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global anticoagulants market was valued at US$ 21,759.3 Mn in 2018 and is projected to expand at a CAGR of 8.0% from 2018 to 2026. Rise in prevalence of obesity, increase in hip and knee surgeries, and surge in cases of coagulation disorders are anticipated to boost the growth of the global market from 2018 to 2026.

Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction.

Request PDF Sample of Anticoagulants Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60924

Increase in Geriatric Population

Dwindling birth rates have led to an increase in the geriatric population. In Japan, people aged 65 and above currently constitute 23% to 25% of the total population. The percentage is projected to reach 38% by 2050. In North America, the estimates are between 13% and 22% and between 16% and 27% in Europe. Rise in standard of health care facilities and availability of advanced treatment options boost life expectancy rates across the world. This in turn increases the geriatric population. According to the UN Population Division, the number of people aged 60 and above is anticipated to increase significantly during 2015–2030. In developed countries, the percentage of people aged 60 and above has increased from 12% in 1950 to 22% in 2011 and is expected to reach 32% by 2050.

On the other hand, in developing countries, the percentage of people aged 60 and above increased from 6% in 1950 to 9% in 2011 and is likely to reach 20% by 2050. Aging makes people prone to fractures and injuries, as their bone density decreases, making them fragile and increasing their susceptibility to falls and arthritis-related fractures. Cardiovascular diseases, kidney disease, osteoporosis, rheumatoid arthritis, and osteoarthritis are common age-related disorders. People aged above 60 are more prone to diseases and disorders. These factors drive demand for anticoagulants products among the geriatric population.

Rise in Cases of Coagulation Disorders

The rise in adoption of Novel Oral Anticoagulants (NOACs) boosts market growth. NOACs target either factor Xa to avoid or to treat thrombosis. These show rapid action and do not require constant monitoring. NOACs also have better efficacy and safety profiles than conventional therapies such as warfarin. Therefore, adoption rate of NOACs has increased in the global anticoagulant market.

Since the introduction of anticoagulants antidotes such as idarucizumab in the market in 2015, acceptance of NOACs has increased, as these eliminate the risk of bleeding. Xarleto and Eliquis are two anticoagulants increasingly preferred by physicians. Xarleto reported a Y-o-Y growth of nearly 10% in 2015, due to increase in volume in some of the key countries such as Japan and Germany. Sales of Eliquis rose by 140.3% due to increase in demand for NOACs globally.

Enquiry for Discount on “Anticoagulants Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=60924

Rise in Prevalence of Obesity

Obesity is a key factor for the rise in the number of people suffering from kidney disorders, cardiovascular disorders, and stroke. This is also attributed to changes in lifestyle and lack of physical activity. According to CDC 2015 report, nearly 950,000 people are affected by pulmonary embolism (PE) or deep vein thrombosis (DVT). Moreover, these conditions account for 65,000 to 100,000 deaths in the U.S. each year. Additionally, more than 10% of the geriatric population of the U.S., which accounts for 25 million people, is affected by kidney diseases associated with thrombosis. This is because aging increases the risk of developing renal and cardiovascular diseases, with chances of thromboembolic and hemorrhagic events also rising. This condition is treated using anticoagulants. Increase in the number of people suffering from DVT and surge in number of surgeries are expected to drive the global anticoagulants market.

Increase in Hip and Knee Surgeries

Rise in the number of knee and hip replacement surgeries increases the risk of DVT. For example, surgeries often result in long period of immobility, which increases the chances of developing DVT due to less blood flow in the body. According to CDC 2016 report, over a million people in the U.S. undergo hip and knee replacement surgeries each year. Moreover, the number of surgical procedures has increased among the geriatric population across the globe. Rise in the number of surgeries increases the risk of developing thromboembolic events. This drives demand for treatment using anticoagulants among patients.

North America to Dominate Global Market

Rise in surgical procedures such as hip and knee replacements is projected to increase the patient pool for treatment with anticoagulants in North America and Europe. According to the Centers for Disease Care and Prevention (2015), around 719,000 knee replacement and 332,000 hip replacement surgeries were performed in the U.S. in 2014. Asia Pacific is expected to be the most lucrative market for anticoagulants from 2018 to 2026. Increase in disposable income, rise in population, and expansion of key players in the region are likely to boost the growth of the anticoagulants market in Asia Pacific.

0 votes

Transparency Market Research (TMR) has published a new report titled, “Anticoagulants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global anticoagulants market was valued at US$ 21,759.3 Mn in 2018 and is projected to expand at a CAGR of 8.0% from 2018 to 2026. Rise in prevalence of obesity, increase in hip and knee surgeries, and surge in cases of coagulation disorders are anticipated to boost the growth of the global market from 2018 to 2026. 

Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. 

Request PDF Sample of Anticoagulants Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60924

Increase in Geriatric Population

Dwindling birth rates have led to an increase in the geriatric population. In Japan, people aged 65 and above currently constitute 23% to 25% of the total population. The percentage is projected to reach 38% by 2050. In North America, the estimates are between 13% and 22% and between 16% and 27% in Europe. Rise in standard of health care facilities and availability of advanced treatment options boost life expectancy rates across the world. This in turn increases the geriatric population. According to the UN Population Division, the number of people aged 60 and above is anticipated to increase significantly during 2015–2030. In developed countries, the percentage of people aged 60 and above has increased from 12% in 1950 to 22% in 2011 and is expected to reach 32% by 2050.

On the other hand, in developing countries, the percentage of people aged 60 and above increased from 6% in 1950 to 9% in 2011 and is likely to reach 20% by 2050. Aging makes people prone to fractures and injuries, as their bone density decreases, making them fragile and increasing their susceptibility to falls and arthritis-related fractures. Cardiovascular diseases, kidney disease, osteoporosis, rheumatoid arthritis, and osteoarthritis are common age-related disorders. People aged above 60 are more prone to diseases and disorders. These factors drive demand for anticoagulants products among the geriatric population. 

Rise in Cases of Coagulation Disorders

The rise in adoption of Novel Oral Anticoagulants (NOACs) boosts market growth. NOACs target either factor Xa to avoid or to treat thrombosis. These show rapid action and do not require constant monitoring. NOACs also have better efficacy and safety profiles than conventional therapies such as warfarin. Therefore, adoption rate of NOACs has increased in the global anticoagulant market.

Since the introduction of anticoagulants antidotes such as idarucizumab in the market in 2015, acceptance of NOACs has increased, as these eliminate the risk of bleeding. Xarleto and Eliquis are two anticoagulants increasingly preferred by physicians. Xarleto reported a Y-o-Y growth of nearly 10% in 2015, due to increase in volume in some of the key countries such as Japan and Germany. Sales of Eliquis rose by 140.3% due to increase in demand for NOACs globally. 

Enquiry for Discount on “Anticoagulants Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=60924

Rise in Prevalence of Obesity

Obesity is a key factor for the rise in the number of people suffering from kidney disorders, cardiovascular disorders, and stroke. This is also attributed to changes in lifestyle and lack of physical activity. According to CDC 2015 report, nearly 950,000 people are affected by pulmonary embolism (PE) or deep vein thrombosis (DVT). Moreover, these conditions account for 65,000 to 100,000 deaths in the U.S. each year. Additionally, more than 10% of the geriatric population of the U.S., which accounts for 25 million people, is affected by kidney diseases associated with thrombosis. This is because aging increases the risk of developing renal and cardiovascular diseases, with chances of thromboembolic and hemorrhagic events also rising. This condition is treated using anticoagulants. Increase in the number of people suffering from DVT and surge in number of surgeries are expected to drive the global anticoagulants market.

Increase in Hip and Knee Surgeries

Rise in the number of knee and hip replacement surgeries increases the risk of DVT. For example, surgeries often result in long period of immobility, which increases the chances of developing DVT due to less blood flow in the body. According to CDC 2016 report, over a million people in the U.S. undergo hip and knee replacement surgeries each year. Moreover, the number of surgical procedures has increased among the geriatric population across the globe. Rise in the number of surgeries increases the risk of developing thromboembolic events. This drives demand for treatment using anticoagulants among patients.

North America to Dominate Global Market

Rise in surgical procedures such as hip and knee replacements is projected to increase the patient pool for treatment with anticoagulants in North America and Europe. According to the Centers for Disease Care and Prevention (2015), around 719,000 knee replacement and 332,000 hip replacement surgeries were performed in the U.S. in 2014. Asia Pacific is expected to be the most lucrative market for anticoagulants from 2018 to 2026. Increase in disposable income, rise in population, and expansion of key players in the region are likely to boost the growth of the anticoagulants market in Asia Pacific.

...